Scortis Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 06-12-2024
- Paid Up Capital ₹ 1.50 M
as on 06-12-2024
- Company Age 26 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 3.20 M
as on 06-12-2024
- Revenue -3.25%
(FY 2019)
- Profit 167.50%
(FY 2019)
- Ebitda -7.79%
(FY 2019)
- Net Worth 22.32%
(FY 2019)
- Total Assets 1.62%
(FY 2019)
About Scortis Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company has closed loans amounting to ₹3.20 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Anjali Modi, Ashish Modi, and Aniruddh Modi serve as directors at the Company.
- CIN/LLPIN
U24232RJ1998PLC014717
- Company No.
014717
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
23 Mar 1998
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- LocationC, Rajasthan
- Telephone
- Email Address
- Website
-
- Social Media
What products or services does Scortis Pharma Limited offer?
Scortis Pharma Limited offers a wide range of products and services, including Ayurvedic & Herbal Health Supplement, Herbal Sexual Health Supplement, Antacid Drugs, Rabeprazole Domperidone Capsule, Allopathic Cough Syrup, Ambroxol Hydrochloride Syrup, API (Active Pharmaceutical Ingredients), Montelukast Sodium Powder, Antipyretic Medication, Paracetamol Tablets.
Who are the key members and board of directors at Scortis Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aniruddh Modi  | Director | 06-Jul-2019 | Current |
| Anjali Modi | Director | 30-May-2000 | Current |
| Ashish Modi | Director | 30-Mar-1998 | Current |
Financial Performance of Scortis Pharma.
Scortis Pharma Limited, for the financial year ended 2019, experienced Minor drop in revenue, with a 3.25% decrease. The company also saw a substantial improvement in profitability, with a 167.5% increase in profit. The company's net worth Soared by an impressive increase of 22.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Scortis Pharma?
In 2019, Scortis Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Kotak Mahindra Prime Limited Creation Date: 12 Feb 2016 | ₹1.70 M | Satisfied |
Bank Of Baroda Creation Date: 23 May 2005 | ₹1.50 M | Satisfied |
How Many Employees Work at Scortis Pharma?
Unlock and access historical data on people associated with Scortis Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Scortis Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Scortis Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
